Efficacy and Safety of Human Bone Marrow-Derived Mesenchymal Stem Cells according to Injection Route and Dose in a Chronic Kidney Disease Rat Model
- Author:
Han Kyu CHAE
1
;
Nayoung SUH
;
Myong Jin JANG
;
Yu Seon KIM
;
Bo Hyun KIM
;
Joomin AUM
;
Ha Chul SHIN
;
Dalsan YOU
;
Bumsik HONG
;
Hyung Keun PARK
;
Choung-Soo KIM
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:International Journal of Stem Cells 2023;16(1):66-77
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background and Objectives:We compared the efficacy and safety of human bone marrow-derived mesenchymal stem cells (hBMSC), delivered at different doses and via different injection routes in an animal model of chronic kidney disease.
Methods:and Results: A total of ninety 12-week-old rats underwent 5/6 nephrectomy and randomized among nine groups: sham, renal artery control (RA-C), tail vein control (TV-C), renal artery low dose (RA-LD) (0.5×10 6 cells), renal artery moderate dose (RA-MD) (1.0×10 6 cells), renal artery high dose (RA-HD) (2.0×10 6 cells), tail vein low dose (TV-LD) (0.5×10 6 cells), tail vein moderate dose (TV-MD) (1.0×10 6 cells), and tail vein high dose (TV-HD) (2.0×10 6 cells). Renal function and mortality of rats were evaluated after hBMSC injection. Serum blood urea nitrogen was significantly lower in the TV-HD group at 2 weeks (p＜0.01), 16 weeks (p＜0.05), and 24 weeks (p＜0.01) than in the TV-C group, as determined by one-way ANOVA. Serum creatinine was significantly lower in the TV-HD group at 24 weeks (p＜0.05). At 8 weeks, creatinine clearance was significantly higher in the TV-MD and TV-HD groups (p＜0.01, p＜0.05) than in the TV-C group. In the safety evaluation, we observed no significant difference among the groups.
Conclusions:Our findings confirm the efficacy and safety of high dose (2×10 6 cells) injection of hBMSC via the tail vein.
